Cloverleaf raises $33M for RNA cancer drugs
Cloverleaf Bio has raised a $33 million seed round to advance engineered transfer-RNA therapeutics for cancer.
Cloverleaf Bio is trying to turn transfer RNA biology into a new therapeutic platform for cancer.
What happened
The company raised an oversubscribed $33 million seed round led by 4BIO Capital. Strategic investors include AbbVie Ventures, Eli Lilly and Boehringer Ingelheim Venture Fund. Cloverleaf is developing engineered transfer-RNA-based therapeutics for oncology.
Why it matters
The round is large for a preclinical seed-stage biotech, and participation from several major pharmaceutical companies adds strategic validation to an emerging therapeutic modality.
The bigger picture
RNA medicine is expanding well beyond the technologies that first brought the category mainstream. Investors are backing increasingly specialised approaches to gene regulation as they search for new ways to reach difficult disease biology.